Immunocodex
1 known investors
Immunocodex develops tolerogenic mRNA vaccines that reprogram immune cells and rebalance the immune system to treat autoimmune diseases. Its platform combines tolerance-inducing signals with disease-specific autoantigens to target conditions such as multiple sclerosis, type I diabetes, rheumatoid arthritis, and celiac disease.
BiotechLongevity
Investors · 1
Frequently asked questions
- What does Immunocodex do?
- Immunocodex develops tolerogenic mRNA vaccines that reprogram immune cells and rebalance the immune system to treat autoimmune diseases. Its platform combines tolerance-inducing signals with disease-specific autoantigens to target conditions such as multiple sclerosis, type I diabetes, rheumatoid arthritis, and celiac disease.
- Who are Immunocodex's investors?
- Immunocodex's investors include Pfizer Venture Investments.